Botox maker Allergan agreed Wednesday to pay $600 million to settle charges it illegally promoted and sold the beauty-enhancing drug through 2005 for unapproved uses like treating headaches, according to the New York Times.
As Allergan slashes jobs in part over Botox's slumping cosmetic sales, it continues with clinical trials that would expand the drug's therapeutic uses. It hopes this year to win U.S. Food and Drug Administration approval for a Botox treatment to help muscle-tightening problems in stroke victims. It's in various phases of clinical trials for applications that treat chronic migraines, overactive bladder and prostate problems.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.